RankAlpha logo
Back to Rankings

ANRO

Alto NeuroscienceB
NYSE / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
At close
2026-07-20
View Chart
Current thesis
The bullish view is that the March financing and roughly $275 million pro forma cash position buy enough runway to let ALTO-207, ALTO-300, and ALTO-100 reset sentiment after the ALTO-101 setback, with ALTO-207 now the lead value driver and potentially the clearest rerating path [#8-K-2026-04-01] [#10-K-2026-03-16].
Posture
Constructive
Lead driver
Momentum
What changed
Momentum remains the lead driver in the composite, 7D delta -3.2.
What can break
ALTO-101 failed to hit statistical significance on primary EEG and cognitive endpoints, reducing pipeline breadth.
Momentum
90
Value
41
Sentiment
41
Setup hits (3d)
0 · Net Neutral
AI TargetsBase $24.00 · Bull $40.00 · Bear $14.00
Data freshness
Prices
As of 2026-07-20
Fundamentals
As of 2026-07-20 • Vendor: Data Vendor v1
Scores
As of 2026-07-20 • Model: HYBRID_IC_RP
AI Memo
As of 2026-04-18 • Model: RankAlpha Sentiment Codex
Investment thesis
As of 2026-07-20
Supporting evidence
What
Grade B · Constructive
Confidence Medium · Net Neutral
Target $34.80
Why
Momentum90 · Δ7d -3.2
Value41 · Δ7d +0.0
Sentiment41 · Δ7d -6.8
So what
Strength-led posture (Net Neutral). Favor watchlist adds and disciplined entries.
Lead driver: Momentum · See technicals
Momentum
90
26% active weight
Current posture
7d trendFlat
Δ7d
-3.2
Δ21d
+10.1
Value
41
39% active weight
Current posture
7d trendFlat
Δ7d
+0.0
Δ21d
-0.1
Sentiment
41
34% active weight
Current posture
7d trendSoftening
Δ7d
-6.8
Δ21d
-3.3
Why this grade

Composite grade B. Momentum 90.3 / Value 41.1 / Sentiment 41.3

Fundamentals (TTM)
As of 2026-07-20
Market Cap
$908.93M
Beta
-
Shares Out
38.87M
P/E (TTM) · Derived
-10.7
P/S (TTM)
-
P/FCF (TTM) · Derived
-11.26
Rev YoY
-
EPS YoY
+42.2%
Gross Margin
-
Op Margin
-
Net Debt
-$152.53M
Current Ratio
20.52
As of 2026-07-20 • Updated nightlySource: Internal modelMethodology